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Peroxisome proliferator-activated receptor g (PPARg)
is a lipid-activated transcription factor regulating
lipid metabolism and inflammatory response in
macrophages and dendritic cells (DCs). These
immune cells exposed to distinct inflammatorymilieu
show cell type specification as a result of altered
gene expression.We demonstrate here amechanism
how inflammatory molecules modulate PPARg
signaling in distinct subsets of cells. Proinflamma-
tory molecules inhibited whereas interleukin-4 (IL-4)
stimulated PPARg activity in macrophages and
DCs. Furthermore, IL-4 signaling augmented PPARg
activity through an interaction between PPARg and
signal transducer and activators of transcription 6
(STAT6) on promoters of PPARg target genes,
including FABP4. Thus, STAT6 acts as a facilitating
factor for PPARg by promoting DNA binding and
consequently increasing the number of regulated
genes and the magnitude of responses. This interac-
tion, underpinning cell type-specific responses,
represents a unique way of controlling nuclear
receptor signaling by inflammatory molecules in
immune cells.
INTRODUCTION
PPARg is a nuclear hormone receptor activated by oxidized fatty
acids and regulating many aspects of lipid metabolism and
inflammation (Itoh et al., 2008; Kliewer et al., 1997; Krey et al.,
1997; Nagy et al., 1998). The major functions include regulation
of adipocyte differentiation (Tontonoz et al., 1994b) and lipidImetabolism in macrophages (Nagy et al., 1998; Ricote et al.,
1998a; Tontonoz et al., 1998). The expression and activity of
PPARg in various cell types are strictly regulated (Kliewer
et al., 1994; Szanto and Nagy, 2005; Szatmari et al., 2004;
Tontonoz et al., 1994b). However, expression of the receptor
and the presence of appropriate ligands are usually not sufficient
to elicit optimal or maximal responses. Further transcriptional
mechanisms contribute to facilitate or restrict responsiveness
leading to cell type- or condition-specific gene expression
pattern (Balint et al., 2005; Carroll et al., 2005; Castrillo et al.,
2003; Laganie`re et al., 2005).
Here, we aimed to understand the impact of extracellular
signals on PPARg activity in macrophages and DCs. Both cell
types represent highly specialized but heterogeneous cell popu-
lations of the immune system. Macrophages originate from bone
marrow progenitors committed to the monocytic lineage (Fried-
man, 2002). Monocytes are recruited to sites of inflammation and
turn into macrophages. The immune phenotype of macrophages
depends on the cellular environment and presence of various
activator molecules (Gordon, 2003). In addition to pathogen
clearance they also regulate resolution of inflammatory
responses. These opposing or polarized activities are initiated
andmaintained by immunomodulatory factors such as cytokines
andmicrobial products andmanifest in distinct activation states.
Proinflammatory molecules, such as interferon-g (IFN-g) and
tumor necrosis factor (TNF) or activators of Toll-like receptors
(TLRs), result in classical activation of macrophages. In contrast,
alternatively activated macrophages, which differentiate upon
IL-4 stimulus (Stein et al., 1992), exhibit a different phenotype
provoking tolerance or T helper 2 (Th2) immune responses
(Cua and Stohlman, 1997). IL-4 induces both Pparg and 12/
15-lipoxygenese, which synthesizes a potential ligand for
PPARg (Huang et al., 1999).
Similarly to macrophages, dendritic cells (DCs) are also
capable of inducing both inflammatory and anti-inflammatory
responses. DCs are sentinels of the immune system and connect
innate and acquired immunity (Steinman et al., 1979). Humanmmunity 33, 699–712, November 24, 2010 ª2010 Elsevier Inc. 699
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monocyte colony stimulating factor (GM-CSF) and IL-4. This
cell type has been shown to be exquisitely responsive to PPARg
activation (Gosset et al., 2001; Nencioni et al., 2002; Szatmari
et al., 2004). This shared requirement of IL-4 invokes an intriguing
similarity between alternatively activated macrophages and
DCs. PPARg activity has been analyzed irrespective of the
inflammatory state of macrophages and DCs and prior reports
focused on downstream effects of PPARg on inflammatory reac-
tions. Based on these, PPARg is considered a negative regulator
of macrophage activation (Jiang et al., 1998; Ricote et al.,
1998b). This is believed to be mediated by the failed induction
of inflammatory genes by proinflammatory transcription factors
(Li et al., 2000; Pascual and Glass, 2006). However, in adipo-
cytes, but also in DCs, PPARg induces as well as represses
hundreds of genes (Guo and Liao, 2000; Szatmari et al., 2007).
These observations suggest that PPARg responses are strin-
gently controlled and determined by cell type and condition-
specific factors. The identification of such factors could explain
differences in PPARg-evoked responses in subtypes of macro-
phages and DCs.
We used gene-specific and global transcriptomics
approaches in mouse and human macrophage subtypes and
DCs to show that proinflammatory molecules inhibited, whereas
IL-4 augmented, both PPARg expression and ligand-induced
transcriptional activity. Pharmacological and genetic evidence
showed that this effect wasmediated by the STAT6 transcription
factor, which acted as a facilitator of PPARg-mediated transcrip-
tion. In addition, we proposed a mechanism by which STAT6 in-
teracted with PPARg and the cooperative binding of the two
factors led to increased PPARg responsiveness. Thus, these
findings provide the molecular mechanism for robust PPARg-
regulated gene expression in these cell types.
RESULTS
Expression of PPARg Is Determined by the Activation
State of Macrophages and DCs
To define conditions of maximal PPARg expression and respon-
siveness, human monocyte-derived macrophages were acti-
vated either with IL-4 or with the proinflammatory cytokines
IFN-g, TNF, or lipopolysaccharide (LPS). AMAC-1, CD206,
CD209, and CD23 were used as markers to define alternative
or CD80, CD83, CD86, and HLA-DR to define classical activation
of macrophages. Immature DCs were differentiated from mono-
cytes with GM-CSF+IL-4, and LPS was used to induce matura-
tion. CD1a andCD209were used asmarkers of DC development
(data not shown) (Geijtenbeek et al., 2000; Porcelli, 1995).
PPARg was induced during monocyte-macrophage transition
(Figure 1A) and its expression was further increased by IL-4
but decreased by IFN-g. Similarly, PPARg was induced upon
differentiation of immature DCs and was modestly upregulated
upon DC maturation with LPS (Figure 1A).
The induction of PPARg by IL-4 was rapid and specific and
translated into increased levels of PPARg protein in macro-
phages (brown nuclear staining) (Figure 1B). Neither PPARa
nor PPARd showed similar expression (Figures S1A–S1C avail-
able online). In contrast, PPARg was essentially missing from
IFN-g-stimulated classically activated cells (Figure S1B). In order700 Immunity 33, 699–712, November 24, 2010 ª2010 Elsevier Inc.to assess the in vivo expression distribution of PPARg in macro-
phages, we surveyed tissues via immunohistochemistry (Figures
S1E–S1Y). PPARg-positive macrophages were identified in
tissues such as Peyer’s patch (Figures S1E–S1G), lamina propria
of normal small intestinal villi (Figures S1H–S1J), reactive lymph
node (Figures S1K–S1M), lymphoepithelial tissue of the tonsil
(Figures S1N–S1P), perivascular macrophages of lymph node
(Figures S1Q–S1S), and the lung (Figures S1T–S1Y), showing
expression preferentially in alternatively activated macrophages
as determined by DC-SIGN staining.
Next, we analyzed the ligand-induced transcriptional activity
of PPARg by treating cells with the agonist Rosiglitazone
(RSG). FABP4 (encoding FABP4, also known as aP2) (Tontonoz
et al., 1994a), a well-established PPARg target gene, was
strongly induced at both mRNA and protein levels in macro-
phages activated with IL-4 and in GM-CSF+IL-4-induced imma-
ture DCs (Figures 1C and 1D). Modest induction of FABP4 by
RSG was observed in nonactivated control and TNF-treated
macrophages and upon IL-4 treatment. Importantly, IFN-g,
IFN-g+TNF, and/or LPS inhibited FABP4 induction in both
macrophages and mature DCs. These effects were specific for
PPARg target genes as shown by the fact that neither LXRa
nor PPARa, d activity was affected (Figure S1D and data not
shown). Therefore, diverse signals could induce PPARg expres-
sion (e.g., LPS, GM-CSF), but only IL-4 could also augment
transcriptional responsiveness as determined by target gene
induction. This finding led to the hypothesis that IL-4 is a facilitator
of PPARg via a mechanism we termed IL-4-induced augmenta-
tion of PPARg response.
IL-4 Is an Enhancer of PPARg Transcriptional
Responses
To test the extent of IL-4 augmentation of PPARg response, we
performed microarray analysis of RSG-treated human macro-
phages (Figures 1E and 1F). In the absence of IL-4, RSG
induced 88 and repressed 32 genes (Figure 1E). IL-4 treatment
resulted in an increase in the number of both the RSG-induced
(336) and -repressed (274) genes. IL-4 not only enabled PPARg
to regulate a larger set of genes (635 versus 120) but also
increased the magnitude of responses on individual genes.
665 genes (out of 730 regulated by RSG in control or IL-
4-treated macrophages) were more responsive to RSG in the
presence of IL-4 (Figure 1F; Table S1). These data suggest
that IL-4-augmented PPARg response applies to the vast
majority of PPARg-regulated genes.
IL-4 Induces Augmented PPARg Response in Both
Mouse Macrophages and DCs
IL-4 increased the expression of Pparg in monocytes isolated
from bone marrow of C57Bl/6 mice (Figure 2A). Fabp4 was
induced by RSG and this change was augmented by IL-4
(Figure 2A). Alternative activation markers such as found in
inflammatory zone 1 (Fizz1), mannose receptor (Mr), chitinase
3-like 3 (Ym1), and arginase 1 (Arg1) were induced by IL-4
(data not shown). RSG treatment barely induced the expression
of PPARg target genes, PPARg angiopoietin-related protein
(Angptl4), or Fabp4 in mousemacrophages whereas the addition
of IL-4 elicited responsiveness to RSG (Figure 2B). Induction of
PPARg target genes showed a similar pattern in mouse bone
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Figure 1. Expression and Activity of PPARg Is Dictated by Cytokines, the Role of IL-4
(A–C) Expression of PPARg (A) and FABP4 (C) was determined by real-time PCR. Humanmonocytes (Mo) were differentiated tomacrophages for 24 hr by attach-
ment or to DCs for 5 days with GM-CSF and IL-4. Macrophages were treated with vehicle (C), IL-4, IFN-g, TNF, IFN-g+TNF (IT), LPS, or GM-CSF (GM) for 24 hr.
LPSwas added on day 5 for 24 hr to induce DCmaturation. In (C) cells were also treated with RSG (R) or vehicle (DMSO:ethanol). Means normalized to cyclophilin
A ± SD. n = 3, p < 0.01 are shown.
(B) PPARg protein was determined by immunostainingwith PPARg antibody. The positive nuclear staining is indicated by purple color (arrows). Methyl-green was
used as nuclear counterstain.
(D) FABP4 protein was detected by immunoblot in human macrophages treated as indicated for 24 hr. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is
the loading control.
(E and F) Humanmacrophageswere cultured for 12 hr in the absence or presence of IL-4 and treatedwith vehicle (C) or RSG (R), gene expressionwas analyzed by
Affymetrix Human GenomeU133 2.0 Plusmicroarrays (n = 3). Signal intensities were normalized to the 50th percentile and to the median expression of genes and
to the vehicle-treated control.
(E) Venn diagrams of RSG-regulated genes (>1.5-fold change, p < 0.05 parametric t test, Benjamini-Hochberg false discovery rate correction).
(F) Heatmaps of 730 probe sets from (E) on the left, and the efficacy (RSG-induced fold changes in IL-4-treated versus controlmacrophages) is shown on the right.
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PPARg-STAT6 Interactionmarrow-derived DCs (Figure S2A). These data demonstrate that
human and murine macrophages and DCs behave similarly with
respect to the effects of IL-4 on PPARg expression and
responsiveness.IPPARg Is Dispensable for IL-4 Signaling
Next, we assessed the relationship between PPARg-IL-4 in
macrophage-specific PPARg-deficient mice carrying loxP-
flanked and null alleles Ppargfl/ (He et al., 2003) and a lysozymemmunity 33, 699–712, November 24, 2010 ª2010 Elsevier Inc. 701
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Figure 2. PPARg Is Dispensable for IL-4 Signaling
(A) Expression of Pparg (left) and Fabp4 (right) in mouse bone marrow-derived monocytes activated as indicated was determined with real-time PCR.
(B) Mouse bone marrow-derived cells (n = 3) were differentiated to macrophages for 10 days, activated as indicated, and expression of Angptl4 (left) and Fabp4
(right) was determined.
(C and D) Expression Fabp4 (C), Arg1, and Ym1 (D) in mouse bone marrow-derived macrophages differentiated from Pparg+/+, Pparg+/, and Ppargfl/LysCre
mice are shown.
(E and F) Bonemarrow-derivedmacrophages from Pparg+/ and Ppargfl/LysCremice (n = 3) were differentiated with M-CSF or MCSF+IL-4 in the absence (C) or
presence (R) of RSG for 10 days. Gene expression was analyzed by Affymetrix Mouse Genome 430 2.0microarrays. Signal intensities were normalized to the 50th
percentile and to the median expression of genes and to vehicle-treated control.
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PPARg-STAT6 Interaction(Lys) Cre transgene (Clausen et al., 1999). PCR assessment
demonstrated near complete recombination (Figure S2B). This
was confirmed by the complete loss of Fabp4 induction by
RSG (Figure 2C). No major differences in the induction of Arg1
or Ym1 markers of alternatively activated macrophages were
detected in IL-4-treated bone marrow-derived macrophages
from wild-type, Pparg+/ LysCre, or Ppargfl/ LysCre mice
(Figure 2D). Similar results were obtained in peritoneal macro-
phages (data not shown).We performedmicroarray experiments
to address the general contribution of PPARg to IL-4 responses
by usingmacrophages fromPparg+/ andPpargfl/ LysCremice.
The vast majority of IL-4-regulated genes showed similar
expression pattern. Neither the number of IL-4-regulated genes
nor the magnitude of responses was affected by the absence of
Pparg (Figures 2E and 2F; Table S2). Importantly, no difference
was detected in the induction of alternative activation markers
by IL-4 (Table S2). The majority of changing genes showed
less than 2-fold difference between the two genotypes (Pparg+/
and Pparg fl/ LysCre) (Figures 2E and 2F). Notably, this is also
true for the nonoverlapping genes (Figure 2F). These turned
out to be the lowest responders to IL-4 (1.5- to 2.5-fold) and
although not significantly, the majority of them are regulated by
IL-4 in both genotypes and no differentially expressed cluster
could be detected in the heatmap or in the gene lists (Figure 2E;
Table S2).
Very little influence of PPARg was found when we compared
the effects of RSG on IL-4-regulated genes and analyzed the
coregulated ones (Figure 2E; Figure S2C). These data indicate
only a modest contribution of PPARg to IL-4 signaling and are
inconsistent with PPARg being required per se for initiation of
alternative activation. The induction of markers of alternative
macrophage activation Ym1, Arg1, or Fizz1 by IL-4 were not
affected by RSG treatment (Figure 2G). This was in agreement
with the global gene expression analysis. We obtained similar
results in Th2 cell-type response-prone BALB/cmice and in peri-
toneal macrophages (data not shown). Taken together, these
data suggest that PPARg is largely dispensable for IL-4-regulated
gene expression in macrophages.STAT6 Is Required for PPARg-Induced Gene Expression
To identify which downstream effectors of IL-4 impact PPARg
expression and/or activity, we used pharmacological inhibitors
that distinguish between STAT6 and insulin receptor substrate-
2 (IRS-2) pathways. Janus Tyrosine Kinase 3 (JAK3) inhibitor
WHI-P131, but not JAK2 inhibitor TYRPhostin (or AG490) or
phosphatidilinositol-3 kinase (PI3K) inhibitor wortmannin, in-
hibited induction of an IL-4-regulated gene, AMAC1, and of
PPARg, indicating that these effects of IL-4 are mediated by
JAK3 (Figure 3A). Similarly, JAK3 but not the JAK2 and PI3K
inhibitors inhibited IL-4-induced augmentation of FABP4 induc-
tion by RSG (Figure 3A). These results are consistent with the
report that JAK3 is the major JAK isoform in myeloid cells (Wit-(E) The heatmap of the expression of IL-4-regulated genes (>2-fold, significan
discovery rate correction, p < 0.05).
(F) Venn diagrams of the IL-4-regulated genes from macrophages of Pparg+/ an
(G) Expression of alternative activation markers, Ym1, Arg1, Fizz1, and that of Pp
Means normalized to cyclophilin A ± SD. n = 3, p < 0.01 are shown.
Ithuhn et al., 1994) and implicated its substrate STAT6 as the
downstream IL-4 effector.
Next, we derived bone marrow-derived macrophages from
wild-type and STAT6-deficient mice. Induction of the alternative
activation marker Ym1 and Pparg by IL-4 shows STAT6 depen-
dence (Figure 3B). IL-4-augmented induction of PPARg target
genes Fabp4 and Angptl4 by RSG was detected only in wild-
type but not in STAT6-deficient macrophages (Figure 3B). To
test whether STAT6 is required for PPARg-mediated gene
expression on a global scale, we performed microarray analyses
and identified RSG-regulated genes in the absence or presence
of IL-4 in wild-type and STAT6-deficient mice (Figures 3C and
3D). TheabsenceofSTAT6hadamajor impactonPPARg-regulated
gene expression. Substantially more genes were induced in the
presence of IL-4 (Figure 3D, upper panels 45 versus 158) and
the fold inductions were larger (Figure 3C). Moreover, the vast
majority (82%) (45+158 genes) of the 225 RSG-induced genes
were regulated by PPARg in a STAT6-dependent manner and
99 out of the 225 RSG-induced genes showed higher expression
upon IL-4 treatment (Table S3). 125 RSG-induced genes were
repressed by IL-4, indicating that the expression pattern of
Angptl4 (i.e., repression by STAT6 and activation by PPARg;
Figure 3B) is not a gene-specific phenomenon but rather charac-
teristic of a set of genes. Interestingly, IL-4 did not increase the
number of genes repressed by RSG: 173 in the control versus
176 in the IL-4-treated cells. However, out of the 318 genes
RSG repressed, 70% showed STAT6 dependence (Figure 3C).
Stat6 deletion decreased the number of RSG-silenced genes in
the absence of IL-4 (Figure 3D, lower panels 148 versus 48),
whereas they were increased in the presence of IL-4 (162 versus
228), indicating the existence of further STAT6-independent
silencing mechanisms. Taken together, these data suggest
that IL-4 augments PPARg activity via STAT6. Furthermore,
STAT6 is required for induction of the majority of PPARg target
genes (82%). These data are consistent with a general, facili-
tating role for STAT6.STAT6 Augments PPARg Activity on Target Gene
Promoters
We took several possible mechanisms of STAT6-mediated
PPARg facilitation into consideration. An obvious one is to see
whether new protein synthesis was required for the enhancing
effect or if it is purely transcriptional. IL-4-dependent induction
of a STAT6-regulated gene, AMAC1, and that of PPARg was
not affected by cycloheximide (CXM), suggesting a direct tran-
scriptional event (Figure 4A). As expected, RSG could activate
PPARg independently of new protein synthesis as reflected in
FABP4 induction (Figure 4A). In the presence of CXM, IL-4 could
still enhance ligand-induced FABP4 expression, suggesting that
STAT6-augmented PPARg response did not require new protein
synthesis. However, FABP4 induction slightly decreased, indi-
cating the contribution of new protein synthesis, most probablyt differences are plotted; n = 3, parametric t test, Benjamini-Hochberg false
d Ppargfl/LysCre mice.
arg from mouse bone marrow-derived macrophages.
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Figure 3. IL-4 Acts through STAT6 to Induce Augmented PPARg Response
(A) Human nonactivated or alternatively activated (IL-4) macrophages were exposed to vehicle (C), proteasome inhibitor MG132, JAK3 inhibitor WHI-P131, JAK2
inhibitor TyrPhostin AGN490 (TyrPh.), or PI-3K inhibitor wortmannin for 6 hr. Simultaneously, cells were treated with vehicle (C) or RSG. Expression of AMAC1,
PPARg, and FABP4 are shown.
(B) Expression of Ym1, Pparg, Fabp4, and Angptl4 was analyzed in bone marrow-derived macrophages isolated from wild-type C56Bl/6 and Stat6/mice and
treated for 10 days as indicated.
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PPARg-STAT6 InteractionPPARg protein production upon IL-4 treatment. In order to eval-
uate the contribution of the increased expression of the receptor,
we transiently transfected cells to overexpress PPARg. PPARg
target gene expression was enhanced by STAT6 when cotrans-
fected and activated by IL-4, which should be independent of the
induction of PPARg (Figure 4B and data not shown).
To prove that IL-4 directly influences PPARg, we excluded
some obvious indirect mechanisms. IL-4 was shown to increase
the production of a PPARg activator, 15d-PGJ2, via inducing 12/
15-lipoxygenase (Huang et al., 1999). IL-4 augmented PPARg
response well before the induction of 15-lipoxygenase in human
macrophages, suggesting that STAT6 is unlikely to act via ligand
generation (Figure 4C). We also excluded that STAT6 would
generate an activator for the retinoid X receptor, the permissive
dimerization partner for PPARg, by using an RXR antagonist
(Figure 4D). We also tested trichostatin A (TSA), a histone deace-
tylase inhibitor, but no difference could be observed in the
nonactivated cells, suggesting that IL-4 does not act via suspen-
sion of histone deacetylation (Figure 4E). Further possible mech-
anism could be that STAT6 induces degradation of a repressor
for PPARg or synthesis of an activator. By using a proteasome
inhibitor, MG132, and translation inhibitor CHX (Figures 3A–
4A), we excluded these possibilities as well. Interestingly,
MG132 not only did not inhibit the enhancement but it further
increased it, suggesting the presence of an activating factor
that is degraded upon activation of PPARg-STAT6. Such factor
could be either the transcription factor itself or its coactivators.
We cannot exclude the possibility that other inhibitory factors
exist, which are activated through the proteasomal pathway.
These experiments left us with the likely possibility that STAT6
acts on the promoter of PPARg target genes.
STAT6 Facilitates PPARg Signaling at the
Transcriptional Level
We chose the prototypic target gene, FABP4 (Tontonoz et al.,
1994a), to study PPARg response at the promoter level. A 5 kb
fragment of the human promoter responded to PPARg activators
and also to IL-4 and this latter could augment the effect of RSG in
a reporter assay in two different cell lines, RAW264.7 and 293T
(Figure 5A). This was surprising, because this fragment did not
contain the human ortholog of the originally identified PPARg
response element, which we term here AdipoPPRE (Figure 5B;
Tontonoz et al., 1994a). By using deletions and mutations, we
identified a response element for PPARg:RXR (Figures 5C and
5D and data not shown). We termed this element MacPPRE
referring to macrophages (Figure 5D). Electrophoretic mobility
shift assays (EMSA) and reporter assays were carried out to
show preferential activation and binding of PPARg to the
enhancers (Figures 5E and 5F). This specificity disappeared
when we mutated the PPARg binding site to the consensus
AGGTCA (Figure S3A). The human ortholog hAdipoPPRE (Tonto-(C and D) Mouse bone marrow-derived macrophages from wild-type C57Bl/6 and
4+RSG. Gene expression was analyzed by Affymetrix Mouse Genome 430 2.0 m
median expression of the gene throughout the experiment and finally to its spec
(C) The heatmap of RSG-induced and repressed genes in the control or IL-4-tre
(D) Venn diagrams of RSG-regulated genes.
Means normalized to cyclophilin A ± SD. n = 3, p < 0.01 are shown.
Inoz et al., 1994a) exhibited similar enhancer activities as the
hMacPPRE (Figures S3B and S3C). Interestingly, the two most
conserved regions in the entire promoter region in mammals
are the Adipo and MacPPREs along with the core promoter indi-
cating their functional importance (Figure 5G; Figure S3C). Unex-
pectedly, we found a consensus conserved STAT6 binding site
downstream to MacPPRE (Figure 5D; Figure S3C), which was
not present in the proximity of AdipoPPRE. This STAT6 response
element was functional and as efficient (Figure 5H) as a known
STAT6 enhancer from the CCL11 gene (Figure 5I; Matsukura
et al., 1999). A short promoter fragment that contained the
composite element (MacPPRE and the STAT6 element) (Fig-
ure 5J) behaved similarly as the original 5 kb fragment (Figure 5A),
indicating that this fragment is responsible for the STAT6-
augmented PPARg response. Mutation of the STAT6 binding
site resulted in the loss of responsiveness to IL-4 (Figure 5K)
without affecting induction by RSG. Mutation of DR1 abolished
RSG-induced activation and also almost completely eliminated
the effects of IL-4 (Figure 5L). The hAdipoPPRE did not show
IL-4 responsiveness (Figure 5M). When isolated DR1s
(consensus or MacPPRE from FABP4) were tested, STAT6
was ineffective in enhancing transcriptional activity (Figures
S5E and S5F). Similarly, activity of a Gal-fusion PPARg could
not be augmented by STAT6 (Figure S5G). Thus these results
indicate the requirement for the STAT6 binding site in the
composite element to augment PPARg response.
In Vivo Binding of STAT6 to PPREs
These in vitro and transfection-based analyses established the
presence of two functional PPREs in the FABP4 promoter, one
of which (MacPPRE) is a complex element conferring IL-4-
augmented PPARg responsiveness. Next, we extended our
studies to observe in vivo occupancy of this element by endog-
enous PPARg and STAT6, and also to see how widespread the
interaction of two factors is on known PPREs and STAT6 binding
sites. Chromatin immunoprecipitation (ChIP) showed IL-4-
induced binding of PPARg and STAT6 to PPREs in 293T cells
transfected with PPARg and STAT6 (Figure 6A). In addition,
both PPARg and STAT6 were enriched on AdipoPPRE in wild-
type macrophages when compared to Stat6/ cells (Figure 6B).
Furthermore, with quantitative ChIP analysis on several known
PPREs and STAT6 binding sites, we could detect PPARg binding
to all the tested elements except the negative control Hoxa1,
and importantly this binding was markedly enriched in wild-
type animals when compared to Stat6/ macrophages (Fig-
ure 6C), indicating that the two transcription factors are likely
to be in the same DNA binding complex in vivo. Importantly,
MacPPRE was more sensitive to the presence of STAT6 than
AdipoPPRE. Thus, STAT6 seems to be enriched on several
PPREs in vivo, suggesting a functional interaction between
STAT6 and PPARg.Stat6/mice were cultured in the presence of vehicle (C), RSG (R), IL-4, or IL-
icroarrays. Signal intensities were normalized to the 50th percentile and to the
ific vehicle-treated control.
ated wild-type macrophages.
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Figure 4. STAT6 Acts on PPARg Response at the Transcriptional Level
(A) Human macrophages were treated with vehicle or CXM, activated with vehicle (C) or IL-4 for 6 hr, and simultaneously vehicle (C) or RSG (R) was added.
Expression of AMAC1, PPARg, and FABP4 were measured with real-time PCR.
(B) 293T cells were transfected withmock, PPARg,STAT6, or PPARg+STAT6 expression vectors and treated as indicated for 24 hr and expression of FABP4was
analyzed by real-time PCR.
(C) Human macrophages were treated as indicated. Expression of FABP4 and 15-lipoxygenase were measured by real-time PCR.
(D) Humanmacrophageswere treatedwith vehicle (C) or IL-4 and simultaneously with vehicle (C), RSG (R) or LG1208 RXR antagonist (ant.) for 24 hr. Expression of
FABP4 was analyzed by real-time PCR.
(E) Human macrophages were treated with vehicle (C) or 100 nM TSA, activated with vehicle (C) or IL-4 for 12 hr, and simultaneously vehicle (C) or RSG (R) was
also added. Expression of FABP4 (left) and PPARg (right) were measured by real-time PCR.
Means normalized to 36B4 (A, B, C) cyclophilin A (D, E) ± SD. n = 3, p < 0.01 are shown.
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PPARg-STAT6 InteractionSTAT6 Facilitates PPARg’s DNA Binding and Interacts
with the Receptor
The binding of STAT6 to PPREs in PPARg target genes’
promoter and the close proximity of STAT6 and PPARg binding
sites in the human FABP4 promoter raised the possibility of
physical interaction between the two transcription factors. We
first performed oligoprecipitation experiments in a monocytic
leukemia cell line, THP-1, and both endogenously expressed
PPARg and STAT6 could be pulled down with wild-type
MacPPRE (Figure 6D). STAT6 binding was detected only after
IL-4 administration. Importantly, mutations in either PPRE or
STAT6 binding sites diminished PPARg binding, whereas
STAT6 binding was eliminated only if STAT6 site was mutated.
Finally, the interaction of PPARg and STAT6 could be also de-
tected by coimmunoprecipitation with tagged, expressed
proteins (Figures 6E and 6F). STAT6 could be pulled down with
PPARg (Figure 6E) and vice versa (Figure 6F). STAT6 could
also be pulled down with purified PPARg protein (Figure 6G).
Although there is a bit of inconsistency regarding the ligand
dependency of PPARg and STAT6 interaction, three out of four
experiments (Figures 6D, 6F, and 6G) support that their interac-
tion is ligand dependent. These data suggest that PPARg and
STAT6 bind the response element in FABP4 promoter in vivo.
Additionally, STAT6, by interacting with PPARg, facilitates and
is required for efficient endogenous PPARg binding.
DISCUSSION
A key issue in immunology is to generate specific cell types often
with opposing activities. It is of importance to understand the
molecular details of the transcriptional mechanisms leading to
the development of such subtypes. We found a diverse pattern
of PPARg expression and activity among the various macro-
phage and DC subtypes, equipping the cells with differential
ability to respond to certain lipid signals. Although several agents
could induce the transcription of PPARg (IL-4, LPS, transforming
growth factor beta), only IL-4 was capable of augmenting its
activity. This enhancement was reflected in the number of genes
and the magnitude of responses. These data are in agreement
with previous reports documenting very few positively regulated
genes and a lower level of responses under proinflammatory
conditions induced by LPS or IFN-g (Welch et al., 2003) and sug-
gested the existance of both positive and negative interactions
between PPARg and cytokine signaling. PPARg has been
described as a negative regulator of macrophage activation by
transrepression (Pascual et al., 2005). However, this mechanism
is unlikely to play a role here. PPARg was also reported to be
required for maturation of alternatively activated macrophages
and disruption of the gene impaired alternative macrophage-
linked functions in mice (Odegaard et al., 2007). Formally, these
data suggested that PPARg acts upstream of IL-4 signaling. We
note that Odegaard et al. used BALB/c mice with Mx-Cre and
rather focused on secondary effects of IL-4 signaling. Their
data might reflect strain-specific differences and/or involvement
of additional complex feedback mechanisms. However, our
results are in agreement with another report also using C57Bl/
6mice (Marathe et al., 2009) and suggest that PPARg is dispens-
able for alternative activation per se. Although direct IL-4
responses are barely altered in PPARg-deficient macrophages,ISTAT6 appears to be required for maximal PPARg activation.
Therefore, PPARg might be more appropriately considered as
a downstream effector in the hierarchy of IL-4-STAT6-PPARg
signaling. This scenario does not formally rule out that in vivo a li-
ganded receptor can contribute to IL-4-regulated events in
a more complex way. Therefore, the role of PPARg in macro-
phages besides lipid handling remains to be mapped, whereas
in human DCs it is linked to lipid metabolism and lipid antigen
presentation (Szatmari et al., 2004, 2007).
IL-4 and PPARg signaling appear to be connected at multiple
levels. IL-4-mediated induction of Pparg and 12/15-lipoxyge-
nase that could generate endogenous activators for PPARg
(Huang et al., 1999) provides two plausible mechanisms for
enhanced response. Induction of PPARg itself is partly respon-
sible for the enhancement, but IL-4-enhanced PPARg activity
appears much earlier than the lipoxygenase mRNA could be
detected. Our results, presented here, point to STAT6 as the
regulator of PPARg response. Our global expression analyses
showed that whereas STAT6 is required for maximal PPARg
response, PPARg was largely dispensable for IL-4 signaling.
This asymmetry is likely to be functionally important to provide
specificity and allow STAT6 to act independently as well. The
basis of this is an interaction by which STAT6 improves PPARg
activity via binding to the enhancer of PPARg target genes.
This is supported by three largely independent lines of evidence:
the gene expression profile of STAT6-deficient macrophages,
ChIP analysis of PPARg and STAT6 target genes, and oligopre-
cipitation with the identified MacPPRE of FABP4. We propose
therefore that STAT6 acts as a licensing factor for PPARg to
provide cell type-specific gene expression by enhancing DNA
binding. Importantly, this interaction is specific; none of the other
characterized receptors (PPARa, d and LXRa) is influenced by
STAT6. Additionally, probably as a special case of a robust IL-
4-augmented PPARg response, a conserved, complex enhancer
(MacPPRE) exists in the FABP4 gene. Themouse ortholog of this
complex element behaves similarly to the human. We could
detect PPARg binding at both MacPPRE and AdipoPPRE in
mouse adipocytes by analyzing recent ChIP-on-chip and ChIP-
seq data (Lefterova et al., 2008; Nielsen et al., 2008). Although
this complex enhancer has a binding site for STAT6 and contrib-
utes to the robustness of the response, it is not clear whether
other genes also use bone fide STAT6 sites or rather protein-
protein interactions for the enhancement. The demonstration
that the two proteins can physically interact provides support
for the latter. To explore this, we have made a model of the
PPARg:RXRa heterodimer (pdb3DZY) and the STAT6 dimer
(based on the STAT3B-DNA complex [pdb1BG1]) on a B-form
MacPPRE DNA element, which suggests that the two protein
complexes sit in close proximity on the DNA (data not shown).
Limited rearrangement of this complex could easily bring the
proteins into direct physical contact. Alternatively, an indirect
interaction might be mediated by corecruitment of a shared cor-
egulator or even by the DNA acting as an allosteric effector, facil-
itating communication between the complexes.
A crosstalk between transcription factors in order to coopera-
tively orchestrate gene expression is not unprecedented.
Estrogen receptor was reported to require the presence of
another transcription factor, Forkhead box A1 (FoxA1), for effi-
cient DNA binding and gene expression regulation (Carrollmmunity 33, 699–712, November 24, 2010 ª2010 Elsevier Inc. 707
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Figure 5. Identification of a Composite PPARg-STAT6 Response Element in the FABP4 Promoter
(A) A reporter construct containing 5 kb fragment of human FABP4 promoter was cotransfected into RAW264.7 and 293T cells with the indicated expression
vectors, and normalized luciferase activity was determined 24 hr after cytokine or ligand treatment (control [C] or RSG [R]).
(B) Schematic structure of the mouse and human FABP4 with the localization of Adipo and MacPPREs.
(C) Deletionmutants of the 5 kb promoter of the human FABP4were cotransfected into 293T cells with mock or PPARg expression vectors. Normalized luciferase
activity was determined 24 hr after ligand treatment (vehicle [C] or RSG [R]).
(D) Sequences of human and mouse MacPPREs of the Fabp4 gene.
(E) The humanMacPPRE wasmutated at the 1st or 2nd half site and tested in transfection assays. Reporter constructs were cotransfected into 293T cells with the
indicated receptor, VP16-PPARg (VP-Pg), VP16-RXR (VP-RXR) expression vectors. Normalized luciferase activity was determined 24 hr after ligand treatment
(vehicle [C], WY14643 [WY], RSG [R], GW501516 [GW], or LG268 [LG]).
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PPARg-STAT6 Interactionet al., 2005; Laganie`re et al., 2005). Recently, C/EBPs were re-
ported to bind to the vicinity of PPARg response elements in
adipocytes (Lefterova et al., 2008; Nielsen et al., 2008). We
suggest that STAT6 is likely to fulfill a similar role for PPARg in
macrophages and DCs. Although the molecular details of these
crosstalks are still elusive, STAT6 might facilitate DNA binding of
PPARg or the two factors could synergistically recruit cofactors
and chromatin remodeling enzymes. Alternatively, STAT6 itself
might act as a coactivator to provide more efficient transactiva-
tion. It is intriguing to speculate that regulated and graded usage
of licensing and facilitating factors (C/EBP and STAT6) could
define specific responses of PPARg leading to distinct gene
expression programs in the various cell types or tissues.EXPERIMENTAL PROCEDURES
Materials
Ligands: LG268, LG1208, gifts from M. Leibowitz (Ligand Pharmaceuticals),
WY14643, Rosiglitazone (RSG), T0901317, and MG132 (Alexis Biochemicals),
GW501516, and GW9662 were gifts from T.M. Willson (GlaxoSmithKline).
Cytokines were obtained from Peprotech. All other reagents were obtained
from Sigma, consumables from Eppendorf, or as indicated.Isolation and Culture of Cells
Humanmonocytes were isolated from healthy volunteer’s buffy coat, obtained
with a Regional Ethical Board permit from the Regional Blood Bank, via CD14
MicroBeads (Miltenyi Biotec) and treated with vehicle (ethanol:dimethyl-
sulfoxide 1:1) or as indicated. For activation we used IL-4 (100 ng/ml),
IFN-g (100 ng/ml), TNF (50 ng/ml), E. coli (O55:B5 serotype) LPS (100 ng/ml).
Thioglycolate-elicited macrophages were harvested from the peritoneal cavity
4 days after injection of 3ml 3% thioglycolate solution; bonemarrow cells were
isolated from the femur of mice. Mouse monocytes were isolated from bone
marrow via negative selection method with magnetic separation (Miltenyi).
Bone marrow cells were differentiated to macrophages by M-CSF (20 ng/ml)
or to DCs by GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) for 10 days. For activation
we used mouse IL-4 (20 ng/ml), IFN-g (20 ng/ml), TNF (20 ng/ml), E. coli
(O55:B5 serotype) LPS (100 ng/ml).Real-Time Quantitative PCR
Total RNAwas isolated with Trizol Reagent (Invitrogen). RNAwas reverse tran-
scribed with High Capacity cDNA Archive Kit (Applied Biosystems). Transcript
quantification was performed by quantitative real-time PCR via Taqman
probes. Transcript levels were normalized to cyclophilin A or 36B4. Details
of primers are in Table S4.Immunoblotting
Total cell lysates or nuclear extracts were resolved in SDS-PAGE and immuno-
blotted with FABP4 (Cayman Chemical), GAPDH (Abcam), Flag (M2, Sigma-Al-
drich), V5 (Serotech), PPARg (E8), or STAT6 (M-20-Santa Cruz) antibodies as
indicated.(F) DNA binding of PPARa (Pa), g (Pg), d (Pd), and RXR (X) to the human MacPPRE
MacPPRE, or its mutants (1st half site-M1, 2nd half site-M2, downstream sequen
(G) Conservation of human FABP4 gene was analyzed by PhastCons conservatio
chromosome 8 genomic position from 82555216 to 82568028 on the negative stra
each position.
(H and I) Reporter constructs with three copies of STAT6 response elements of hu
and normalized luciferase activity was determined 24 hr after IL-4 (100 ng/ml) ex
(J–M) Composite response elements of FABP4 gene containing both PPRE and
STAT6 expression vectors. Human MacPPRE (J), STAT6 (K), or PPARg (L) bindin
Normalized reporter activities as means ± SD, n = 3, p < 0.01 are shown.
ITransient Transfection
RAW264.7 cells were electroporated (300V for 15 ms); COS1 and HEK293T
cells were transfected in triplicates with polyethyleneimine. Luciferase reporter
activity was determined with Luciferase Assay System (Promega) and normal-
ized to beta-galactosidase activity.
Electrophoretic Mobility Shift Assay
PPARa, g, d and RXR were in vitro transcribed and translated with T7 Quick
TNT Kit (Promega). DNAwas labeled in a random priming reaction (Fermentas)
with radioactive [32P]dATP. For competition, nonlabeled cold DNA (2–103), for
supershift experiments PPARg (Perseus) or RXR (Perseus) antibodies were
used.
Pull-Down Assays
Human PPARg1 was tagged with streptavidin-binding protein and expressed
in Rosetta BL21 (Novagen). After induction with 40 mM isopropyl-D-thiogalac-
topyranoside, PPARg1 was purified with streptavidin-resin. Whole cell lysates
of STAT6 or mock-transfected HEK293T cells were added to the resin and
after washing analyzed by immunoblotting.
Coimmunoprecipitation
HEK293T cells were transfected with STAT6-V5 and Flag-PPARg expression
vectors. V5 (AB Serotech) or Flag M2 (Sigma) antibodies were used for immu-
noprecipitation and subsequent immunoblotting.
Chromatin Immunoprecipitation
ChIP was performed as described earlier (Balint et al., 2005) with anti-PPARg
(CS-133-100, Diagenode and preimmune serum), anti-STAT6 (M20-Santa
Cruz), or control immunoglobulin. Enrichment of genomic loci was quantitated
with real-time PCR.
Mice
Mice carrying null or floxed alleles of Pparg were described previously (Barak
et al., 1999). These mice were bred with LysCre transgene animals obtained
from I. Fo¨rster (Univ. of Munich) (Clausen et al., 1999). Stat6/ mice were
purchased from The Jackson Laboratory. Animals were housed under minimal
disease conditions and the experiments were carried out under institutional
ethical guidelines and licenses.
Microarray Analysis
Microarray analysis was performed with Affymetrix microarrays (Human
Genome U133 Plus 2.0 or Mouse Genome 430 2.0) and standard protocols.
Microarray hybridizations were carried out at the Debrecen Clinical Genomics
Center Microarray Facility. Analysis was performed with GC-RMA on the cel
files in GeneSpring 7.3 (Agilent). For each condition, three biological replicates
were analyzed. Signal intensities were normalized to the 50th percentile (per
chip), then to the median expression of the certain gene throughout the exper-
iment (per gene), and finally each chip was normalized to its specific vehicle-
treated control. Changing genes were called based on a t test (parametric,
variances assumed to be equal, with Benjamini and Hochberg false discovery
rate), p < 0.05 and at least 1.5-fold changes. For annotation we used The Func-
tional Annotation Tool at DAVID Bioinfomatics Resources 6.7 (National Insti-
tute of Allergy and Infectious Diseases [NIAID]).was analyzed by EMSA. Cold competitors of consensus DR1 (DR1), wild-type
ce outside the DR1-M3) were used.
n scores for placental mammals. The plotted region corresponds to the hg18
nd. The y axis shows the PhastCons conservation scores (in the range 0–1) for
man CCL11 (H) or FABP4 (I) gene were transfected into 293T cells with STAT6
posure.
STAT6 binding sites were transfected into 293T cells along with PPARg and
g site mutant of MacPPRE and human AdipoPPRE (M) were tested.
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Figure 6. STAT6 Colocalizes and Interacts with PPARg In Vivo and In Vitro
(A) 293T cells were transfected with PPARg and STAT6 expression vectors and ChIP was performed with anti-STAT6 and anti-PPARg. IL-4-induced enrichment
of FABP4 MacPPRE, AdipoPPRE, LXRa-PPRE, and CD36-PPRE elements were analyzed by real-time PCR. GAPDH promoter was used as negative control.
Enrichment over IgG and over control samples is presented.
(B) PPARg and STAT6 ChIP was performed on bone marrow-derived macrophages from wild-type and Stat6/mice. Enrichment of Fabp4 PPRE over the IgG
and over the wild-type samples is presented.
(C) PPARg ChIP was performed on bone marrow-derived macrophages from wild-type and Stat6/mice. Enrichment of PPREs (Acsl1, Angptl4, Cd36, osteo-
pontin, pyruvate dehydrogenase kinase-4 [Pdk4], stearoyl-Coenzyme A desaturase-1 [Scd1], Fabp4 Adipo-, and MacPPRE), STAT6 response elements of Fizz1,
Tarc1, and Ym1, and the negative control Hoxa1 over the IgG and over the wild-type samples is presented.
(D) hMacPPRE coprecipitates endogenous STAT6 and PPARg from THP-1 cells. Biotin-labeled oligonucleotides corresponding to wild-type (WT), PPRE
(M-PPRE), STAT6 site (M-S6), or double mutant (M-PPRE-S6) MacPPRE were incubated with equal amounts of nuclear extracts harvested from vehicle ()
or IL-4+RSG (IL-4+R)-treated (+) cells. Pulled down proteins were immunoblotted with the indicated antibodies. Input represents 1.67% of oligoprecipitated
material.
(E and F) 293T cells were transfected with mock, V5-STAT6 (V5-S6), or V5-STAT6+Flag-PPARg (V5-S6+Flag-Pg) as indicated. Coimmunoprecipitation from
whole cell lysates was performed with V5 or Flag antibodies and presence of V5-STAT6 (E) and Flag-PPARg (F) were analyzed by immunoblotting.
(G) PPARgwas expressed in bacteria and purifiedwith streptavidine-resin, and STAT6was pulled down fromwhole cell lysates ofmock or V5-STAT6-transfected
293T cells. Proteins were analyzed by immunoblotting with V5 antibody.
Means normalized to input ± SD. n = 3, p < 0.05 are shown.
Immunity
PPARg-STAT6 InteractionImmunohistochemistry
Immunostaining for PPARg was carried out on paraffin-embedded cellular
blocks with biotin-free Catalyzed Signal Amplification IHC detection kit (CSAII,
Dako) and VIP substrate (Vector Labs). Sections were counterstained with710 Immunity 33, 699–712, November 24, 2010 ª2010 Elsevier Inc.methyl-green. Double immunofluorescence (IF) stainings were carried out on
human tissues obtained from the archives of surgical tissue specimens of
the Department of Pathology, University of Debrecen. For PPARg staining,
we used the red fluorescent tetramethyl-rhodamine (TMR)-tagged tyramide
Immunity
PPARg-STAT6 Interaction(Perkin-Elmer). All other IF for double stainings (CD68, DC-SIGN) were made
sequentially via biotinylated secondary antibodies followed by a streptavi-
din-FITC development for green fluorescence (Dako). Sections were counter-
stained with 4’,6-diamidino-2-phenylindole (DAPI, Vector Laboratories) (blue
nuclear fluorescence).
Bioinformatic Analysis
The PhastCons conservation scores for placental mammalian species were
obtained from the UCSC site calculated from the MULTIZ (UCSC/Penn. State
Bioinformatics) 44 vertebrate species whole-genome alignment.
Oligoprecipitation Assays
Nuclear extracts from THP1 cells treated with vehicle or RSG+IL-4 were
prepared as described earlier (Nagy et al., 2009). Precleared extracts were
incubated with annealed biotin-labeled oligonucleotides representing
MacPPRE and streptavidin-agarose. Captured protein was analyzed by immu-
noblotting with PPARg (E-8) and STAT6 (M-20) antibodies (Santa Cruz).
Statistical Tests
All data are presented asmeans ± SD and based on experiments performed at
least in triplicate. Statistical tests were performed on the fold changes via
unpaired (two tail) t test, p < 0.01.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE16387.
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